Clinical relevance of FLT3 receptor protein expression in Indian patients with acute leukemia

Asia-Pacific Journal of Clinical Oncology

Volumn 6, Issue 4, 2010, Pages 306-319

  Vora, Hemangini H ^a   Shukla, Shilin N ^b   Brahambhatt, Birwa V ^a   Mehta, Shalvi H ^a   Patel, Nupur A ^a   Parikh, Sonia K ^c   Shah, Kruti N ^a   Shah, Pankaj M ^d  

^a Immunohistochemistry and Flowcytometry Division   (India)

^b Medical Oncology and Hon Deputy Director Research and Education   (India)

^c Medical Oncology   (India)

^d CIVIL HOSPITAL   (India)

Author keywords

AML; B ALL; Flow cytometry; FLT3 protein

Indexed keywords

ASPARAGINASE; CD135 ANTIGEN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLINATE CALCIUM; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; PREDNISONE; TIOGUANINE; VINCRISTINE;

ACUTE BIPHENOTYPIC LEUKEMIA; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; INDIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; FEMALE; FLOW CYTOMETRY; FMS-LIKE TYROSINE KINASE 3; HUMANS; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78649795419     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2010.01322.x     Document Type: Article

References (44)

1. Rosner O, Schiff C, Pebusque MJ, Marchetto S, Tonelle C, Toiron Y. Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood 1983; 82: 1110-19.
2. Kuchenbauer F, Kern W, Schoch C, Kohlmann A, Hiddemann W. Detailed analysis of FLT3 expression levels in acute myeloid leukemia. Hematologica 2005; 90: 1617-25.
3. CD135, FMS-related tyrosine kinase 3 in WIKIPEDIA, the Free Encyclopedia. [updated 6 November2010]. Available from.
4. Meierhoff G, Dehmel U, Gruss HJ etal. Expression of FLT3 receptor and FLT3 ligand in human leukemia-lymphoma cell lines. Leukemia 1995; 9: 1368-72.
5. Drexler HG. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia 1996; 10: 261-70.
6. Dehmel U, Zaborski M, Meierhoff G etal. Effects of FLT3 ligand on human leukemia cells. I. Proliferative response of myeloid leukemia cells. Leukemia 1996; 10: 261-70.
7. Dehmel U, Quentmeier H, Drexler HG. Effects of FLT3 ligand on human leukemia cells. II. Agonistic and antagonistic effects of other cytokines. Leukemia 1996; 10: 271-80.
8. Lisovsky M, Estrov X, Zhang X etal. FLT3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of BCl-2 and Bax. Blood 1996; 88: 3987-97.
9. Nakao M, Yokota S, Iwai T etal. Internal tandem duplication of the FLT3 gene found in acute myeloid leukemia. Leukemia 1996; 10: 1911-8.
10. Kiyoi H, Naoe T, Nakano Y etal. Prognostic implications of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999; 93: 3074-80.
11. Yokota S, Kiyoi H, Nakao M etal. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 1997; 11: 1605-9.
12. Rombouts WJC, Blokland I, Lowenberg B, Ploemacher RE. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the FLT3 gene. Leukemia 2000; 14: 675-83.
13. Kottaridis P, Gale RE, Frew ME etal. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 1752-9.
14. Thiede C, Steudel C, Mohr B etal. Analysis of FLT3 activating in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326-35.
15. Whitman SP, Archer KJ, Feng L etal. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem of FLT3: a cancer and leukemia group B study. Cancer Res 2001; 61: 7233-9.
16. Schnittger S, Schoch C, Dugas M etal. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for detection of minimal residual disease. Blood 2002; 100: 59-66.
17. th ASH Annual Meeting and Exposition, Dec 2008.
18. Peng HL, Zhang GS, Gong FJ, Shen JK, Zhang Y. Fms-like tyrosine kinase (FLT) 3 and FLT3 internal tandem duplication in different types of adult leukemia: analysis of 147 patients. Croat Med J 2009; 49: 650-9.
19. Brown P, Levis M, Shurtleff S, Campana D, Downing J. FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood 2005; 105: 812-20.
20. Zheng R, Levis M, Piloto O, Brown P, Baldwin B. FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. Blood 2004; 103: 267-74.
21. Ozeki K, Kiyoi H, Hirose Y, Iwai M, Ninomiya M. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood 2004; 103: 1901-8.
22. Wergeland L. Bergen open research archive: FLT3 receptor tyrosine kinase in AML and its modulation of the p53/Hdm2/Bcl-2 pathway. [updated 20 November 2007].Available from.
23. Chauhan P, Bhushan B, Verma S, Saluja S, Sharma M. Immunophenotypic and clinical findings in adult acute myeloid leukemia with FLT3 internal tandem duplication. HGM 2008; Poster Abstract.
24. Mathews V, Thomas M, Srivastava V, George B, Srivastava A. Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen. Hematologica 2007; 92: 994-5.
25. Dunna N, Kagita S, Damineni S, Rajappa S, Digumarti R. NPM1/FLT3 ITD gene mutation profiling in acute leukemia: a pilot study. HGM 2008; Poster Abstract.
26. Hasan SK, Sazawal S, Dutta P, Pillai LS, Kumar B. Impact of FLT3 internal tandem duplications on Indian acute promyelocytic leukemia patients: prognostic implications. Haematology 2007; 12: 99-101.
27. Bene MC, Castoldi G, Knapp W etal. European Group for the Immunological Classification of Acute Leukemias. Proposals for the immunological classification of acute leukemias. Leukemia 1995; 9: 1783-6.
28. Rothe G, Schmitz G. Working Group on Flow Cytometry and Image Analyses Consensus protocol for the flow cytometric immunophenotying of hematopoietic malignancies. Leukemia 1996; 10: 877-95.
29. Nakao M, Janssen JW, Erz D, Seriu T, Bartram CR. Tandem duplication of the FLT3 gene in acute lymphoblastic leukemia: a marker for the monitoring of minimal residual disease. Leukemia 2000; 14: 522-4.
30. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002; 100: 1532-42.
31. Abu-Duhier FM, Goodeve AC, Wilson GA, Gari MA, Peake IR. FLT3 internal tandem duplication mutations in adult acute myeloid leukemia define a high-risk group. Br J Haematol 2000; 111: 190-5.
32. Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001; 97: 2434-9.
33. Kiyoi H, Yanada M, Ozekia K. Clinical significance of FLT3 in leukemia. Int J Hematol 2005; 82: 85-92.
34. Auewarakul C, Leecharendkeat A, Thongnoppakhun W, Limwongse C, Tocharoentanaphol C. Mutations of AML1 in non-M0 acute myeloid leukemia: six novel mutations and a high incidence of cooperative events in a South-east Asian population. Haematologica 2006; 91: 675-8.
35. Bacher U, Haferlach T, Kern W, Haferlach C, Schnittger S. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica 2007; 92: 744-52.
36. Kainz B, Fonatsch C, Schwarzinger I, Sperr W, Jager U. Limited value of FLT3 mRNA expression in the bone marrow for prognosis and monitoring of patients with acute myeloid leukemia. Haematologica 2005; 90: 695-6.
37. Kruzik PO, Irish JM, Nolan GP, Perez OD. Analysis of protein phosphorylation and cellular signaling events by flow cytometry: techniques and clinical applications. Clin Immunol 2004; 110: 206-21.
38. Ravandi F, Jilani I, Estey E, Kantarjian H, Dey A. Soluble phosphorylated FMS-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML). Leuk Res 2007; 31: 791-7.
39. Small D. Targeting FLT3 for treatment of leukemia. Semin Haematol 2008; 45: S17-S21.
40. Xu B, Li L, Tang JH, Zhou SY. Detection of FLT3 gene and FLT3/ITD mutation by polymerase chain reaction-single-strand conformation polymorphism in patients with acute lymphoblastic leukemia. Di Yi Jun Yi Da Xue Xue Bao 2005; 25: 1207-10.
41. Graf M, Hecht K, Reif S, Pelka-Fleischer R, Pfister K. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies. Eur J Haematol 2004; 72: 89-106.
42. Armstrong S, Mabon M, Silverman L, Li A, Gribben J. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood 2004; 103: 3544-6.
43. Munoz L, Aventin A, Villamor N, Junca J, Acebedo G. Immunophenotypic findings in acute myeloid leukemia with FLT3 internal tandem duplication. Hematologica 2003; 88: 637-45.
44. Syampurnawati M, Tatsumi E, Furuta K, Takenokuchi M, Nakamachi Y. HLA-DR-negative AML (M1 and M2): FLT3 mutations (ITD and D835) and cell-surface antigen expression. Leuk Res 2007; 31: 921-9.